“calcitonin-gene-related-peptide” Archives

in
Entry Author Date Location
Biohaven’s Migraine Pill Is the Latest CGRP Drug to Win the FDA’s OK 02/27/20 New York
Lundbeck’s Alder Bio Bet Pays Off With FDA Approval of Migraine Drug 02/23/20 National
Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More 01/03/20 National
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments 05/03/19 National
Teva’s Approved Migraine Drug Fails Again to Blunt Rarer Headache 04/23/19 New York
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines 09/28/18 Indiana
Teva Wins FDA Nod for Migraine Drug, Sets Price in Line with Amgen’s 09/14/18 National
Teva’s Migraine Drug Fails in Phase 3 for Chronic Cluster Headaches 06/15/18 National
Allergan’s Migraine-Reducing Pill Hits Study Goals, Heads to Phase 3 06/11/18 New York
Drug Price Watchdog ICER Deems Amgen Migraine Drug “Cost-Effective” 06/01/18 National
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines 05/17/18 National
Amgen Migraine Decision Looms, Maybe the Next Drug Price Fight, Too 05/16/18 National
Teva Migraine Drug Likely Delayed by Manufacturing Trouble 02/08/18 National
Alder Plans for FDA Filing After Migraine Drug Posts Strong Results 01/08/18 Seattle
With Good Data From Rival Migraine Drugs, Doctors Foresee Price Headaches 11/29/17 San Francisco
Teva Seeks to Keep Pace in Migraine Drug Race With Trial Results 05/31/17 New York
Eli Lilly Migraine Drug Hits Study Goals, Paves Way for FDA Filing 05/12/17 Indiana
With New Data, Alder Keeps Pace in Migraine Drug Race 03/28/16 Seattle
Labrys Turns Stalled Pfizer Program into $200M+ Teva Buyout 06/03/14 San Francisco
Alder BioPharmaceuticals Hits IPO Trail Looking for $115M 03/19/14 Seattle
East Coast Biotech Roundup: JP Morgan Edition 01/17/14 Boston
Arteaus, With $18M From Atlas and OrbiMed, Forges Ahead on Migraine-Prevention Drug 10/19/11 Boston
Page 1 of 1